Clinical Trial Update: Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating erlotinib in patients with resected, early-stage non-small cell lung cancer harboring EGFR mutations; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-11